These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 1712106)
1. Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites. Myoken Y; Kayada Y; Okamoto T; Kan M; Sato GH; Sato JD Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5819-23. PubMed ID: 1712106 [TBL] [Abstract][Full Text] [Related]
2. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. Gitay-Goren H; Soker S; Vlodavsky I; Neufeld G J Biol Chem; 1992 Mar; 267(9):6093-8. PubMed ID: 1556117 [TBL] [Abstract][Full Text] [Related]
3. Anabolic effects of 1,25-dihydroxyvitamin D3 on osteoblasts are enhanced by vascular endothelial growth factor produced by osteoblasts and by growth factors produced by endothelial cells. Wang DS; Miura M; Demura H; Sato K Endocrinology; 1997 Jul; 138(7):2953-62. PubMed ID: 9202240 [TBL] [Abstract][Full Text] [Related]
4. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Kanno S; Oda N; Abe M; Terai Y; Ito M; Shitara K; Tabayashi K; Shibuya M; Sato Y Oncogene; 2000 Apr; 19(17):2138-46. PubMed ID: 10815805 [TBL] [Abstract][Full Text] [Related]
5. Effect of FGF-1 and FGF-2 on VEGF binding to human umbilical vein endothelial cells. Chen JH; Wang XC; Kan M; Sato JD Cell Biol Int; 2001; 25(3):257-60. PubMed ID: 11352499 [TBL] [Abstract][Full Text] [Related]
6. Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer. DiSalvo J; Bayne ML; Conn G; Kwok PW; Trivedi PG; Soderman DD; Palisi TM; Sullivan KA; Thomas KA J Biol Chem; 1995 Mar; 270(13):7717-23. PubMed ID: 7706320 [TBL] [Abstract][Full Text] [Related]
7. Specific binding of vascular permeability factor to endothelial cells. Olander JV; Connolly DT; DeLarco JE Biochem Biophys Res Commun; 1991 Feb; 175(1):68-76. PubMed ID: 1998521 [TBL] [Abstract][Full Text] [Related]
8. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. Houck KA; Leung DW; Rowland AM; Winer J; Ferrara N J Biol Chem; 1992 Dec; 267(36):26031-7. PubMed ID: 1464614 [TBL] [Abstract][Full Text] [Related]
9. Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects. Bikfalvi A; Sauzeau C; Moukadiri H; Maclouf J; Busso N; Bryckaert M; Plouet J; Tobelem G J Cell Physiol; 1991 Oct; 149(1):50-9. PubMed ID: 1719003 [TBL] [Abstract][Full Text] [Related]
10. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Fairbrother WJ; Christinger HW; Cochran AG; Fuh G; Keenan CJ; Quan C; Shriver SK; Tom JY; Wells JA; Cunningham BC Biochemistry; 1998 Dec; 37(51):17754-64. PubMed ID: 9922141 [TBL] [Abstract][Full Text] [Related]
11. An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. Siemeister G; Schirner M; Reusch P; Barleon B; Marmé D; Martiny-Baron G Proc Natl Acad Sci U S A; 1998 Apr; 95(8):4625-9. PubMed ID: 9539788 [TBL] [Abstract][Full Text] [Related]